ICICI Venture today announced signing of a definitive share purchase agreement to sell all common shares of RFCL’s Vetnex Animal Health to Pfizer Animal Health of world’s largest drug maker Pfizer. The acquisition is expected to close by August 2009, subject to necessary regulatory approvals.
Vetnex Animal Health is a part of RFCL, a significant stake in which was acquired by ICICI Venture from Ranbaxy Laboratories for Rs 125 crore in 2005.
Though ICICI Venture did not disclose much, sources said the deal was worth over Rs 200 crore and that Vetnex had an annual turnover of Rs 100-120 crore. French animal healthcare majors Virbac and Sanofi-Aventis were also in the race, they said. When contacted, RFCL executives declined to comment.
Vetnex is a market leader in poultry, livestock and pet healthcare and is one of the top three players in the Indian animal healthcare market. The company is valued at about Rs 1,400 crore.
RFCL, which operates in chemicals, diagnostics and animal healthcare sectors, had de-merged its animal health division into Vetnex earlier this year.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
